Sirona Biochem Announces the Termination of Supply Agreement with Rodan + Fields
VANCOUVER, British Columbia, Jan. 16, 2023 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) announces...
Pharmaceutical
Cytovance Biologics Announces Ping Zhang as Chief Executive Officer
OKLAHOMA CITY, Jan. 16, 2023 (GLOBE NEWSWIRE) -- Cytovance® Biologics, a leading biopharmaceutical contract development and manufacturing organization (CDMO) of...
Linnea SA Receives Swiss Narcotics License allowing for the Production and Exportation of High THC Active Pharmaceutical Ingredients
Swissmedic grants Linnea a narcotics license. Allowing them to now be one of the first to produce and export GMP Certified...
Calibre Scientific Acquires Glass Chemicals, a Comprehensive Provider of Laboratory Consumables, Equipment and Services in Spain
LOS ANGELES, Jan. 16, 2023 (GLOBE NEWSWIRE) -- Calibre Scientific is pleased to announce the acquisition of Glass Chemicals (the “Company”), a...
Clover Provides Updates on COVID-19 Vaccine Commercial Launch and Strategic Priorities in 2023
-- China commercial launch in multiple provinces and municipalities expected to begin in Q1 2023, and Clover anticipates a significant...
CLINUVEL Trial Results Show Drug Reduces DNA Damage
Results in “children of the moon” disorder have implications for populations at highest risk of skin cancerMELBOURNE, Australia, Jan. 16,...
POINT Biopharma Completes Randomization in PNT2002’s Phase 3 SPLASH Trial
Enrollment for the randomization phase of SPLASH completed prior to EOY 2022, meeting previous guidanceINDIANAPOLIS, Jan. 12, 2023 (GLOBE NEWSWIRE)...
RespireRx Pharmaceuticals Inc. Establishes ResolutionRx Ltd in Australia to Develop Its Pharmaceutical Cannabinoid Platform
Glen Rock, N.J., Jan. 12, 2023 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Markets: RSPI) (“RespireRx” or the “Company”), a...
Software Effective Solutions (OTC: SFWJ) Secures Distribution Agreement with Netafim, World’s Leading Drip Irrigation Technology Firm
Software Effective Solutions (OTC: SFWJ) Secures Distribution Agreement with Netafim, World’s Leading Drip Irrigation Technology Firm Netafilm - Purpose, Vision,...
Rapid Micro Biosystems Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue
Full year 2022 commercial revenue expected to be between $17.0 million and $17.2 million Finished 2022 with approximately $140 million...
Panbela Starts Phase II Trial of CPP-1X-T for Recent Onset Type I Diabetes, in Collaboration with Indiana University School of Medicine and JDRF
MINNEAPOLIS, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the...
Vallon Pharmaceuticals and GRI Bio to Present at the Virtual Investor 2023 Companies to Watch Event
Live video webcast on Tuesday, January 17, 2023 at 1:00 PM ET PHILADELPHIA, PA and LA JOLLA, CA, Jan. 11,...
Zynerba Pharmaceuticals Announces Publication in the Journal of Neurodevelopmental Disorders Describing the Role of the Endocannabinoid System and Cannabidiol Therapy in Fragile X Syndrome
Comprehensive data review suggests a central role for the endocannabinoid system (ECS) in neuronal development, cognitive function and in the...
PharmaTher Holdings Provides Update for KETARX™ (Racemic Ketamine) Development Programs and Expected Milestones for 2023
Company aims to commercialize wholly-owned KETARX™ (racemic ketamine) for mental health, neurological and pain disorders Company aims to seek FDA...
Clene Nanomedicine Announces Participation in Renmark Virtual Non-Deal Roadshow Series on January 18 and January 23
SALT LAKE CITY, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its...
CRISPR Therapeutics to Participate in B. Riley Securities’ 3rd Annual Oncology Conference
ZUG, Switzerland and CAMBRIDGE, Mass., Jan. 11, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on...
Recce Pharmaceuticals to be Granted Anti-Viral Patent in Australia for RECCE® Anti-Infectives
SYDNEY, Australia, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q), the Company developing a new class of synthetic...
Aprea Therapeutics Announces Dosing of First Patient in Phase 1/2a Clinical Trial of Oral ATR Inhibitor ATRN-119 for the Treatment of Advanced Solid Tumors
DOYLESTOWN, Pa., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic...
Fresh Tracks Therapeutics Announces Publication of Preclinical Data for FRTX-02, a Potential First-in-Class Oral DYRK1A Inhibitor, in the Peer-Reviewed Journal of Translational Autoimmunity
Topline results from SAD and MAD parts of FRTX-02 Phase 1 study expected in Q1 2023BOULDER, Colo., Jan. 11, 2023...
ClearPoint Neuro Reports Fourth Quarter and Full Year 2022 Preliminary Revenue Results and Guidance for Full Year 2023 Revenue
SOLANA BEACH, Calif., Jan. 11, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform...